Gilead Sciences agreed to acquire Tubulis, a German biotechnology company focused on antibody-drug conjugates (ADCs), for up to $4.8 billion.
Gilead Sciences Inc. → Tubulis GmbH · Healthcare · Acquisition
Gilead Sciences’ acquisition of Tubulis GmbH enhances Gilead’s oncology capabilities through next-generation antibody-drug conjugate (ADC) technologies.
Gilead Sciences agreed to acquire Tubulis, a German biotechnology company focused on antibody-drug conjugates (ADCs), for up to $4.8 billion.